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Abstract
Human rhinovirus (RV) infections are the principle cause of common colds and precipitate asthma and COPD exacerbations.
There is currently no RV vaccine, largely due to the existence of ,150 strains. We aimed to define highly conserved areas of
the RV proteome and test their usefulness as candidate antigens for a broadly cross-reactive vaccine, using a mouse
infection model. Regions of the VP0 (VP4+VP2) capsid protein were identified as having high homology across RVs.
Immunization with a recombinant VP0 combined with a Th1 promoting adjuvant induced systemic, antigen specific, cross-
serotype, cellular and humoral immune responses. Similar cross-reactive responses were observed in the lungs of
immunized mice after infection with heterologous RV strains. Immunization enhanced the generation of heterosubtypic
neutralizing antibodies and lung memory T cells, and caused more rapid virus clearance. Conserved domains of the RV
capsid therefore induce cross-reactive immune responses and represent candidates for a subunit RV vaccine.
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Introduction
Human rhinovirus (RV) infections are the most frequent cause of
the common cold [1] and are highly associated with exacerbations
of asthma and COPD [2,3,4]. Despite the great disease burden and
healthcare costs therefore attributable to RV infections, there is
currently neither a vaccine nor specific anti-viral therapy available.
The requirements for immunity to RV are poorly understood.
Experimental and natural infections induce antibodies which
provide some protection against re-infection with the same RV
serotype [5,6,7]. Intranasal and intramuscular inactivated virus
vaccinations similarly induce neutralizing antibodies and provide
protection against disease induced with the same RV serotype
[8,9]. There are however greater than 100 serotypes of RV [10],
divided into major and minor groups based on receptor usage and
A and B groups based on antiviral sensitivity and nucleotide
sequence [11,12], and a further ,50–60 RV species more recently
defined as group C RVs based on sequence data alone [13,14].
Serological variability amongst RVs therefore means that vaccines
designed to generate neutralizing antibodies are unlikely to
provide sufficiently broad protection to prevent the frequent
infections which occur throughout life.
Alternative vaccination strategies based on inducing T cell
responses to conserved antigens have been explored for a number
of pathogens, including respiratory viruses [15,16]. An advantage
of this approach lies in the ability of T cells to recognize internal
virus proteins which are typically more highly conserved than
surface exposed regions containing neutralizing antibody epitopes.
T cells are therefore potentially cross-reactive against different
virus strains, as has been shown with influenza viruses [17,18], for
which surface antigenic variability is also an obstacle to effective
vaccine design.
For RVs, naturally occurring memory T cells can be cross-
serotype responsive [19,20] and immunization with RV peptides
has been suggested to be capable of inducing cross-serotype
reactive T cells in mice [21]. Most of the naturally occurring RV-
specific memory T cells characterized to date have shown a Th1/
Tc1 bias [19,20]. In vitro responses to RV by mixed PBMCs have
been associated with virus shedding or cold symptoms after
subsequent infection [22] but there is no evidence that naturally
occurring RV-specific memory T cells specifically provide benefit
in terms of virus control or disease symptoms in vivo. Here we show
that a vaccine composition which elicits a Th1/Tc1 biased T cell
response to conserved RV antigens could have efficacy.
We took a bioinformatic approach to identify regions of the RV
polyprotein which are conserved across A and B group and major
and minor receptor binding group viruses, and which might be
used as immunogens in a cross-reactive vaccine. As in similar
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analyses by others [11], we show that areas of the capsid VP0
protein are highly conserved amongst RVs. Immunization with
VP0 protein from major group RV16 combined with Th1
promoting adjuvants induced antigen-specific, type I orientated
T cell responses in the airways, enhanced neutralizing antibody
responses to infection and caused a more rapid decrease in lung
virus load in mice. Importantly, these effects were seen in mice
infected with heterologous RV strains, indicating that capsid
protein immunization could provide broadly cross-reactive
immunity against RVs.
Results
The VP0 protein is highly conserved amongst RVs
Using published amino acid sequences we defined areas of the
RV polyprotein which are conserved across A and B species RVs.
The methodology for determining amino acid sequence conser-
vation amongst RVs is described in materials and methods. We
did not find well conserved sequences covering both A and B
species RVs, but within each species three regions were identified
as highly conserved in agreement with similar sequence compar-
isons carried out previously [11] and therefore represented
candidate antigens. These were amino acids 1–191 and 243–297
in the N-terminus of the polyprotein, and the C-terminal domain
of the RNA polymerase (Fig. S1a). The two N-terminus regions lie
within the VP4 and VP2 capsid proteins, of which VP0 is the
natural precursor. Because VP0 contains both very highly
conserved internal (VP4) and surface exposed regions with
neutralizing epitopes (VP2), VP0 was chosen as the antigen for
further studies. Sequences from RV16, a major group A species
RV were used to allow study of cross-reactivity to minor group RV
strains which can infect wild type mice [23]. Figure S1 shows
detailed analysis of the high sequence conservation within VP0
(Fig. S1b), the amino acid sequence of the RV16 VP0 immunogen
(Fig. S1c) and comparison of RV16 VP0 with VP0 sequences of
minor group RVs 1B, 29 and 14 used subsequently (Fig. S1d).
Immunization induces a VP0 specific, cross-serotype
immune response
We first assessed the immunogenicity of subcutaneously
delivered RV16 VP0 protein. Analysis of antibody responses by
western blot showed that RV16 VP0 - specific IgG was detectable
in serum 28 days post-immunization (Fig. 1a). In mice immunized
with VP0 protein alone, VP0-specific IgG1 and IgG2c, Th2 and
Th1 associated IgG isotypes respectively, were detected.
To assess whether a Th1/Tc1 orientated response to infection is
associated with improved disease outcome, we attempted to induce
a Th1 skewed response to RV16 VP0 using a combination of
incomplete freund’s (IFA) and CpG adjuvants (IFA/CpG). The
addition of IFA/CpG to the immunogen caused a more
prominent IgG2c response (Fig. 1a).
Having established that RV16 VP0 is immunogenic, we next
assessed the T cell response to immunization by measuring
splenocyte cytokine production in response to stimulation with
VP0, or control polymerase, peptides (described in Fig. S2).
Stimulation with control polymerase peptides did not induce
cytokine production (Fig. 1b,c). In both ELISPOT (Fig. 1b) and
cytometric bead array (Fig. 1c) assays VP0 peptide pool
stimulation induced IL-5, or both IL-5 and IFN-c production by
cells from mice immunized with VP0 protein alone, indicating a
Th2 or mixed Th1/Th2 orientated response. As expected, the
addition of IFA/CpG adjuvant to the immunogen caused a near
complete suppression of IL-5 and substantial increase in IFN-c
responses (IL-5 p,0.01, IFN-c p,0.001 RV16 VP0+IFA/CpG vs
RV16 VP0 treatment for VP0 peptide pool stimulation) (Fig. 1b,c).
Importantly, splenocytes from major group A species RV16 VP0
protein immunized mice produced cytokines when stimulated with
VP0 peptides based on minor group A species RV1B and major
group B species RV14 sequences, indicating cross-serotype
reactivity.
Immunization enhances airway T cell responses to
infection with a heterologous RV strain
We next determined the effect of (major group, A) RV16 VP0
plus IFA/CpG immunization on responses to intranasal challenge
with RV1B, a heterologous minor group A virus (Fig. 2a).
We observed no signs of clinical disease in animals which were
immunized prior to infection consistent with our previous
experience of mouse RV infections. Differential staining of
bronchoalveolar lavage (BAL) leukocytes showed a significantly
increased magnitude of lymphocyte response to infection in
immunized and infected (RV-immunized) vs adjuvant treated and
infected (RV-Adjuvant) mice (day 6 post-infection p,0.001)
(Fig. 2b). To examine this enhanced lymphocyte response further,
T cells in BAL and lung were analyzed by flow cytometry. CD4+
T cell numbers were substantially increased in both BAL and lung,
and CD8+ T cell number was increased in BAL of RV-immunized
vs RV-adjuvant treated mice on day 6 post-infection (p,0.01 BAL
and lung CD4+ T cells, p,0.001 BAL CD8+ T cells) (Fig. 2c).
The response in RV-immunized mice was dominated by CD4+ T
cells whose number was ,10-fold greater than CD8+ T cells by
day 6 post-infection. In infected mice, the proportion of BAL and
lung T cells expressing the activation marker CD69 was also
significantly increased by immunization (RV-Immunised vs RV-
adjuvant p,0.001 lung CD4+ and CD8+ T cells day 1–14,
p,0.05 BAL CD4+ & CD8+ T cells d6 & d14)(Fig. 2d).
Immunization-induced increases in T cell number were associated
with enhanced levels of T cell chemokine CXCL10 (p,0.001 RV-
Immunised vs RV-adjuvant at 24 hrs post infection)(Fig. 2e).
Author Summary
Human rhinovirus infections cause the majority of com-
mon colds as well as asthma and chronic obstructive
pulmonary disease (COPD) exacerbations. The disease
burden attributable to rhinoviruses is therefore huge.
Despite this and the fact that human rhinoviruses were
discovered over 50 years ago, there are currently no
specific antiviral therapies or vaccine available. The lack of
a rhinovirus vaccine can at least in part be attributed to the
fact that rhinoviruses like other pathogens have high
variability in surface antibody binding regions, resulting in
.100 serotypically distinct strains. We have defined areas
of the rhinovirus polyprotein which are highly conserved
across strains and which may therefore induce cross-
reactive immune responses capable of providing broader
protection. Using a mouse model, we show that immuni-
zation with a recombinant rhinovirus capsid protein
induces cross-reactive cellular and humoral immune
responses. After subsequent infection, immunization en-
hances both neutralising antibody and lung effector and
memory T cell responses, expediting virus clearance.
Importantly these effects were evident upon challenge
with multiple heterologous rhinovirus serotypes, indicat-
ing that immunization with conserved rhinovirus capsid
proteins may represent a viable strategy for producing a
broadly cross-reactive vaccine.
Immunization with a Conserved Rhinovirus Protein
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Immunization induces antigen-specific lung Th1
responses to infection
We also examined the effect of immunization with RV16 VP0
on the polarity and antigen specificity of airway T cells after
heterologous RV1B challenge. Immunization significantly in-
creased the levels of signature Th1 (IFN-c), Th17 (IL-17a) and
Th2 (IL-4) cytokine mRNAs in lung tissue of RV1B challenged
mice (p,0.01 RV-immunised vs RV-adjuvant at 24 hrs post-
infection) (Fig. 3a). Consistent with the use of the Th1-promoting
adjuvants, this response was dominated by IFN-c in RV-
Figure 1. Immunization induces systemic, cross-serotype, type I immune responses. Mice were immunized subcutaneously with RV16 VP0
protein or buffer, with or without IFA/CpG adjuvant, as described. Spleens and serum were harvested 28 days post-immunization. (a) Serum IgG
binding to (RV16 VP0 or control polymerase (39 Pol)) viral proteins were assessed by western blot. (b & c) Splenocytes were stimulated with VP0 or
Polymerase (39 Pol) peptide pools as indicated and (b) IFN-c and IL-5 producing cells were enumerated by ELISPOT assay and (c) supernatant FN-c
and IL-5 protein levels were measured by cytometric bead array. n = 10 mice/group ***P,0.001, **P,0.01.
doi:10.1371/journal.ppat.1003669.g001
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immunized mice. IFN-c and IL-17a protein were detected at
24 hrs post-infection only in immunized and challenged mice
(p,0.001 vs RV-adjuvant treatment). IFN-c again dominated
with concentrations ,206 higher than IL-17a (Fig. 3b). IL-4
protein was undetectable in BAL of all groups.
Since immunization generated cross-reactive, VP0-specific
cells in the spleen (Fig. 1), we also determined if cross-reactive
memory cells were recruited to the airways after infection by
measuring IFN-c production by antigen stimulated lung leuko-
cytes using ELISPOT assays. The frequency of IFN-c producing
lung cells was greatest in mice both immunized and RV
challenged (Fig. 3c). Stimulation with homosubtypic immunogen
RV16 VP0, with heterotypic RV1B and RV14 VP0 peptide
pools, and with live RV1B all induced similar IFN-c responses
(all viral stimuli p,0.001 RV-Immunised vs RV-adjuvant).
RV16 VP0 immunization therefore induces cross-reactive Th1/
Tc1 responses in the lung in response to RV1B challenge that
are of significantly greater magnitude than with RV infection
plus adjuvant treatment or immunization with sham infection
(Fig. 3c).
Figure 2. Immunization enhances airway lymphocyte responses to heterologous RV infection. (a) Mice were immunized subcutaneously
with RV16 VP0 protein plus IFA/CpG adjuvant, or with IFA/CpG adjuvant only, and infected intranasally with RV1B (RV-Immunized, RV-Adjuvant) or
sham PBS-challenged (PBS-Immunized). (b) Lymphocytes in BAL were counted by cytospin assay. (c) BAL and lung CD4+ and CD8+ T cells were
enumerated and (d) their expression of the activation marker CD69 was assessed by flow cytometry. (e) CXCL10/IP-10 protein in BAL was measured
by ELISA. n = 4 mice/group. Statistics indicated are for RV-immunized vs RV-adjuvant groups. ***P,0.001, **P,0.01, *P,0.05.
doi:10.1371/journal.ppat.1003669.g002
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Immunization increases T cell responses to infection with
a more distantly related RV serotype
RV16 and RV1B belong to different receptor binding groups
(major and minor respectively), but are highly related at the
nucleotide level [11] and the amino acid level (Fig. S1d) within
VP0. To establish if immunization induces more broadly cross-
reactive responses we therefore assessed responses to infection with
the more distantly related [11] minor group A virus, RV29 (Fig.
S1d).
BAL cell staining revealed increased lymphocyte numbers in
RV16 VP0 immunized and RV29 infected (RV-immunized) vs
adjuvant treated and RV29 infected (RV-adjuvant) mice (p,0.01
day 4, p,0.001 day 7 post-infection)(Fig. 4a). Total and activated
CD4+ (Fig. 4b & 4c) and CD8+ (Fig. 4d & 4e) T cell number in
BAL and lung tissue were also significantly increased compared to
infection or immunization treatments alone. Upon stimulation
with RV antigens in ELISPOT assays, IFN-c producing lung
leukocyte frequency was greater in response to challenge serotype
(RV29) stimulation in RV-immunized vs RV-adjuvant treated
mice (p,0.001)(Fig. 4f). Similar increases were apparent after
stimulation with RV1B (p,0.001) and RV14 (p,0.05) derived
VP0 peptide pools, again indicating cross-serotype reactivity. We
also determined lung T cell-specific IFN-c production by
intracellular flow cytometry staining and observed early (day 1)
increases in CD8+ and later (day 6) increases in CD4+ T cells
expressing IFN-c in RV-immunized vs RV-adjuvant, or PBS-
immunized treatment groups (RV-immunised vs RV-adjuvant
p,0.001) (Fig. 4g).
Immunization enhances lung memory T cell responses to
heterologous virus infection
Significantly increased numbers of activated CD4+ T cells
persisted in the lungs of immunized and RV infected mice on day
14 post-infection (Fig. 4c). To determine if this represented
enhanced generation of local T cell memory we performed flow
cytometric staining for memory markers on lung CD4+ T cells.
The proportion and absolute number of CD4+ T cells with a
CD44+CD62Llow, effector memory, phenotype was significantly
higher in RV29 infected and RV16 VP0 immunized mice
compared to either treatment alone (p,0.05). However, no
differences were observed between groups in CD44+CD62Lhigh
central memory cells (Fig. 4h & 4i).
Immunization enhances neutralizing antibody responses
to heterologous virus infection
As neutralizing antibodies are believed important in protection
against RV infection, we next investigated the effect of immuni-
zation on generation of humoral immune responses by measuring
serum and BAL immunoglobulin binding to RVs, and the ability
of sera to neutralize RV infection in vitro.
ELISA binding assays showed that immunization with RV16
VP0 in the absence of RV infection weakly induced RV29 and
RV1B binding antibodies (Fig. S3a–d). The cross-reactivity of
antibodies induced by RV16 VP0 immunization against multiple
virus serotypes was also shown by Western Blot (Fig. S3e). When
combined with RV1B or RV29 infection in vivo, immunization
generated more rapid and greater magnitude of RV-specific serum
Figure 3. Immunization enhances lung Th1/Tc1 responses to heterologous RV infection.Mice were immunized subcutaneously with RV16
VP0 protein plus IFA/CpG, or with IFA/CpG adjuvant only and infected intranasally with RV1B or sham PBS-challenged, as described. (a) Lung tissue
IFN-c, IL-17a and IL-4 mRNA levels measured by Taqman qPCR. (b) T cell cytokine proteins in BAL measured by ELISA. (c) Lung cells harvested 6 days
after intranasal challenge were incubated with the indicated stimuli and IFN-c producing cells were enumerated by ELISPOT assay. n = 4 mice/group.
Statistics indicated are for RV-immunized vs RV-adjuvant groups. ***P,0.001, **P,0.01.
doi:10.1371/journal.ppat.1003669.g003
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Figure 4. Immunization enhances effector and memory T cell responses to infection with a more distantly related RV. Mice were
immunized subcutaneously with RV16 VP0 protein plus IFA/CpG or with IFA/CpG adjuvant only and infected intranasally with RV29 or sham PBS-
challenged, as described. (a) Lymphocytes in BAL were counted by cytospin assay. (b & c) Total and CD69 expressing CD3+CD4+T cells in BAL (b) and
lung (c) were enumerated by flow cytometry. (d & e) Total and CD69 expressing CD3+CD8+T cells in BAL (d) and lung (e) were enumerated by flow
cytometry. (f) Lung cells harvested 6 days after intranasal challenge were incubated with the indicated virus, protein, peptide pool or control stimuli
and IFN-c producing cells were measured by ELISPOT assay. (g) Lung cells were stimulated with PMA and ionomycin and intracellular IFN-c
expression in CD4+ and CD8+ T cells was measured by flow cytometry. (h) Graphical data and (i) representative flow cytometry dot plots of CD62L
and CD44 memory cell staining of lung CD4+ T cells on day 14 post-infection. n = 4 mice/group. Statistics indicated in a to g are for RV-immunized vs
RV-adjuvant groups. ***P,0.001, **P,0.01, *P,0.05.
doi:10.1371/journal.ppat.1003669.g004
Immunization with a Conserved Rhinovirus Protein
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and BAL IgG responses, and BAL IgA responses, than RV-
adjuvant treatment (Fig. S3a–d), indicating that immunization also
boosts antibody responses upon subsequent heterotypic RV
infection.
We next investigated if enhanced heterotypic antibody respons-
es included boosting of neutralizing activity. Immunization with
RV16 VP0 alone did not induce neutralizing antibodies in
uninfected mice (Fig. 5a,b). Neutralization of the infecting serotype
virus was observed with day 14 post-infection sera of mice treated
with adjuvant and infected with RV1B (Fig. 5a), but this was not
observed for RV29 (Fig. 5b), suggesting that the neutralizing
antibody response to RV in the mouse is either weak or absent.
Prior immunization of RV challenged mice however induced both
a more rapid induction (day 6) and greater peak titer of
neutralizing antibodies (RV1B infection: 50% inhibition dilution
[ID50] day 14 RV-immunized 1:3218 vs RV-adjuvant 1:160)
(Fig. 5a–c). Antibodies induced by RV16 VP0 immunization only
neutralized the in vivo infecting RV serotype (data not shown).
These data indicate that immunization with RV16 VP0 is
capable of substantially enhancing neutralizing antibody responses
to in vivo infection with heterologous RVs.
Immunization accelerates virus clearance
Finally, we determined whether the Th1 and neutralizing
antibody responses induced by immunization conferred any
benefit on virus control. Immunization resulted in more rapid
virus clearance, as RV1B RNA was undetectable on days 4 & 6 in
RV-immunized but not in adjuvant treated mice (Fig. 6).
Figure 5. Immunization enhances and accelerates the generation of neutralizing antibodies to a heterologous infecting virus. Mice
were immunized subcutaneously with RV16 VP0 protein plus IFA/CpG or with IFA/CpG adjuvant only and infected intranasally with RV1B, RV29 or
sham PBS-challenged as described. Sera were assayed for their ability to prevent cytopathic effect caused by the same RV serotype administered for
in vivo infection, using a crystal violet HeLa cell neutalization assay. (a) Neutralization of RV1B cytopathic effect by sera from RV1B-infected or PBS-
challenged mice. (b) Neutralization of RV29 cytopathic effect by sera from RV29 infected or PBS challenged mice. Top dotted lines; serum only
(uninfected) controls. Bottom dotted lines; virus infected (no serum) control. Open circles are ATCC reference guinea pig anti-sera. Data points
represent sera pooled from 4 mice/treatment group. (C) Serum 50% inhibition dilution (ID50) values for RV1B and RV29 neutralization. ND; not
detected.
doi:10.1371/journal.ppat.1003669.g005
Immunization with a Conserved Rhinovirus Protein
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Discussion
The unmet medical need attributable to RV infections is
enormous but serotypic heterogeneity represents a major barrier
to the development of an RV vaccine. We therefore identified
regions of the RV polyprotein which are highly conserved amongst
RVs to select potential constituents of a broadly cross-reactive
subunit vaccine and tested their efficacy in a mouse model. We
found that domains of the VP4 and VP2 (VP0) capsid proteins
were highly conserved across A and B species RVs.
Immunization with recombinant RV16 VP0 protein increased
the magnitude of airway T cell, especially CD4+ T cell, responses
to infection consistent with the recruitment to and expansion of
immunization-induced memory T cells in the airways. Although
the CD4+ T cell dominance of this response contrasts with the
prominent CD8+ CTL responses characteristic of other respira-
tory virus infections [24,25,26], there is evidence to suggest this is
representative of naturally occurring RV infection [20,27].
CD4+ T cells provide B cell help and can also possess direct
cytotoxic effector function similar to CD8+ CTL and could
therefore have both direct and indirect roles in RV control
[28,29,30,31].
The observed increases in airway T cell number in immunized
and infected mice might in part be explained by the enhanced
levels of the T cell recruiting chemokine CXCL10 measured in
BAL 24 hrs after infection. Locally induced or systemically
transferred memory T cells have previously been shown to
increase airway innate immune mediators after influenza chal-
lenge via both IFN-c dependent and independent mechanisms
[32]. CXCL10 is an interferon inducible gene and in our studies
the increase in CXCL10 might be explained by the enhanced
levels of IFN-c in the lungs of immunized and infected mice at the
same timepoint after infection.
There is limited data available regarding T cell polarization
during RV infections in humans. In the mouse model little T cell
cytokine response was measurable in the airways of infected and
adjuvant treated mice, but by combining Th1 promoting
adjuvants with the VP0 immunogen we observed a strong type I
response to RV challenge and an acceleration of rhinovirus
clearance. This is the first clear evidence that such enhancement of
type I polarized T cell responses to RV provides benefit in terms of
virus control [19,22,33]. In addition, asthmatics are a major target
group for RV vaccination and Th1/Tc1 responses may also
suppress type 2 responses which are associated with increased
disease severity during experimental RV-induced disease exacer-
bations in atopic asthmatics [33], a hypothesis which can now be
tested by utilising the mouse RV-induced asthma exacerbation
model we have described previously [23]. A key requirement for
an RV vaccine is broad cross-reactivity against the ,150 strains.
Human memory CD4+ T cells specific for conserved influenza
proteins have been demonstrated to be cross-subtype responsive
[17,18] and we hypothesized that immunization with conserved
RV proteins might induce similarly cross-reactive cells. We found
that RV16 VP0 immunization induced systemic T cells that were
responsive to VP0 peptides from heterologous group A and group
B RV serotypes. Following subsequent challenge, cells recovered
from the lungs were reactive to the RV16 derived immunogen, to
heterologous group A live viruses with which mice were infected
and to group B RV VP0 peptides. This cross-reactivity likely
represents the recognition of conserved epitopes within VP0,
primarily by CD4+ T cells given their greater expansion. Whether
this cross-reactivity will be similarly evident in human populations
with diverse MHC is not known but a previous study encourag-
ingly showed that VP2 peptides can induce cross-haplotype
responses in mice [21]. Further, whilst these studies provide proof
of concept for the generation of cross-reactive T cells to RVs,
further studies should determine if similar cross-reactivity is seen
for the ,100 other known RV serotypes. Likewise the large
number of genetically defined C species RVs which are to date not
well characterized [13]. Whether vaccine induced enhancement of
Th1 cell responses to RV will prove a safe strategy for preventing
RV induced disease awaits confirmation in a clinical trial.
However, influenza vaccines are already licenced which use
adjuvants which promote strong CD4+ T cell responses and have
been shown to be safe [34,35].
Immunization also induced IgG antibodies which bound
multiple RV serotypes and following subsequent infection,
enhanced heterologous infection serotype specific antibody levels
in serum and BAL. Notably, this included a BAL IgA response
which as we have shown previously [36] is otherwise weak or
absent after a single infection in this model. Importantly,
immunization with RV16 VP0 also enhanced neutralizing
antibody responses to infection with the heterosubtypic viruses
RV1B and RV29. The fact that generation of neutralizing
antibody was dependent upon infection suggests that the effect of
immunization on production of serotype-specific neutralizing
antibodies following subsequent infection results from B cell help
provided by broadly responsive immunization-induced T cells.
Enhancement of both the speed and magnitude of antibody
responses may provide benefit in terms of accelerating virus
clearance and reducing duration of disease caused by naturally
occurring infections with virus strains heterologous to that upon
which the sequence of the immunogen is based.
Consistent with a role for immunization-induced responses in
enhancing virus control, we found that viral RNA was cleared
more rapidly from the lungs of immunized mice after subsequent
virus infection. This effect was more evident at later stages of
infection, which is likely attributable to the fact that virus
replication in this mouse model is short-lived compared to human
infection, lasting only around 24 hrs [23,33,37] and therefore
before enhanced T cell responses are apparent. The fact that T
cell and antibody responses were able to speed virus clearance in a
mouse model where replication is short lived suggests however that
in man, where replication is much more robust and of longer
duration [33,37], the magnitude of benefit might be substantially
greater.
Figure 6. Immunization accelerates virus clearance. Mice were
immunized subcutaneously with RV16 VP0 protein plus IFA/CpG or with
IFA/CpG adjuvant only and infected intranasally with RV1B or sham PBS-
challenged. RV RNA in lung tissue was measured by Taqman qPCR. n = 4
mice/group. n.d., not detected.
doi:10.1371/journal.ppat.1003669.g006
Immunization with a Conserved Rhinovirus Protein
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Pre-existing neutralizing antibodies to RVs provide protection
against infection and symptoms in humans [6,7] and in addition to
accelerating virus clearance during the first naturally acquired
infection with a given serotype, enhanced neutralizing antibody
responses may provide better and more durable protection against
future RV infections. Likewise the enlarged effector memory T cell
pool in immunized persons, because local memory T cells are
likely to respond rapidly to secondary challenge and are proposed
to possess more potent anti-viral function than systemic memory
cells [38,39]. Immunization with VP0 may therefore generate
serotype specific protective humoral and cross-reactive lung T cell
memory responses to natural infection. Because RV infections are
frequent throughout life, typically comprising 8–10 per year in
young children and 2–5 per year in adults [40], natural infection
following immunization could result in protection against a broad
range of previously unseen RVs.
In summary, immunization with a recombinant RV capsid
protein enhanced airways Th1 cell and airways and systemic
antibody responses to infection with heterologous virus serotypes.
Immunization also accelerated virus clearance. This study
therefore provides proof of principle for a broadly cross-reactive
subunit vaccine for RV infections.
Materials and Methods
Ethics statement
All animal studies were conducted according to UK home office
legislation (Animals (Scientific Procedures) Act 1986), project
licence number PPL 70/7234, or under approval of the Sanofi
Pasteur Animal Care Committee protocol numbers F.DI.R-
VI005.Ms, F.DI.RVI006.Ms and F.DI.RVI007.Ms.
Identification of conserved sequences
The design of the VP0 immunogen was based on linear
sequence conservation amongst RVs. All RV sequences were
retrieved from the National Center for Biotechnology Information
(NCBI) Genbank database on August 23, 2007 and sequence
alignments were generated for all available complete polyproteins
from HRV-A and HRV-B using the MUSCLE algorithm [41].
This included 136 polyprotein sequences across 74 A species
serotypes and 51 sequences across 25 B species serotypes to take
account of variability both between serotypes and between
different field strains within serotypes. A phylogenetic tree was
elaborated using the maximum likelihood method from the
Seaview application [42] and bootstrap values were calculated to
assess the robustness of the nodes. A global consensus sequence
was generated from the alignments using the Jalview application
[43]. Global consensus sequences were extracted from each
alignment and frequency of occurrence for each major amino acid
was calculated (Fig. S1 a,b).
Expression and purification of antigens
The VP0 nucleotide sequence was optimized for E. coli
expression and synthesized (Life Technologies, Saint Aubin,
France). Antigen was expressed as a recombinant protein fused
to a SUMO tag using the pET-SUMO vector (Invitrogen, Saint
Aubin, France). The Overnight Express Autoinduction System 1
(EMD Millipore, France) was used with BL21lDE3 E. coli
transfected with the pET-SUMO plasmid encoding RV16 VP0.
As it was expressed into the insoluble fractions as inclusion bodies,
purification was then performed according the manufacturer
recommendations (Invitrogen) adapted for insoluble proteins.
Briefly, SUMO-fused proteins extracted with Tris/NaCl buffer
containing 8M Urea were loaded onto Nickel sepharose columns
(Pharmacia) for Immobilized Metal Affinity chromatography
(IMAC). Purification was performed by applying an imidazole
gradient to the column. Recombinant proteins eluted into the
250 mM imidazole fractions were further dialysed against a
digestion buffer (Tris 20 mM, NaCl 150 mM pH 8.0 containing
2M Urea) to cleave the SUMO moiety by the SUMO ULP-1
protease. The RV16 VP0 obtained after digestion was applied
onto a second Nickel sepharose column to remove the SUMO
moiety, the non-cleaved protein and the protease-containing His
tag (Fig. S1e). The cleaved RV16 VP0 obtained after the second
purification step was further dialysed against Tris/NaCl buffer
(Tris 20 mM, NaCl 150 mM, Arginine 0.5 M, pH 8.0).
Peptide pools for RV1B and RV14 were generated for the VP0
and 39 polymerase regions. Peptides were synthesized and purified
commercially (JPT, Germany). Peptides were 15mers overlapping
by 11 amino acids, with each pool comprising approximately 40
peptides. The sequences upon which the respective peptide pools
are based are presented in Figure S2.
RV propagation
RV serotype 1B and 29 for in vivo studies were propagated in H1
HeLa cells (American Type Tissue Culture Collection (ATCC) ref
CRL-1958) and purified and titrated as described previously [23].
RV stocks were originally obtained from the ATCC. A purified,
uninfected HeLa cell lysate preparation was generated as a control
for virus-specific immunoglobulin assays.
Mice
6–8 week old, wild type, female C57BL/6 mice were purchased
from Charles River Laboratories (UK, or Saint Germain sur
l’Arbresle, France) and housed in individually ventilated cages.
In vivo protocols
For immunogenicity experiments (Fig. 1), mice were immunised
subcutaneously (s.c.) on days 0 and 21 with 10 mg RV16 VP0
protein, Incomplete Freund’s and CpG (IFA/CpG) adjuvant
(10 mg CpG 1826 (MWG Eurofins, Germany) and 100 mL IFA),
or with adjuvant alone. Further controls received protein buffer
(Tris 20 mM, NaCl 150 mM, Arginine 0,5 M pH 8,0) with or
without IFA/CpG adjuvant. Mice were culled on day 49.
For RV challenge studies mice were immunised s.c. on days 0
and 21 with a solution containing; 10 mg RV16 VP0 protein,
10 mL CpG oligonucleotide (100 mM ODN 1826) and 40 mL IFA
(Sigma-Aldrich, UK) in sterile PBS, or adjuvant alone. On day 51,
mice were challenged intranasally with 56106 TCID50 RV
serotype 1B or 29, or mock challenged with PBS, and were culled
at the indicated timepoints.
Tissue harvesting and processing
Bronchoalveolar lavage (BAL) was performed and processed as
previously described [23]. For lung leukocyte analyses, tissue was
homogenized using the GentleMACS tissue dissociator (Miltenyi
Biotech, UK) and homogenized tissue was digested in RPMI
medium containing 1 mg/ml collagenase type XI and 80units/mL
bovine pancreatic Dnase type IV (both Sigma-Aldrich). Red cells
were lysed with ACK buffer. For RNA extraction, an apical lobe
of the right lung was excised and stored in RNAlater stabilization
buffer (Qiagen, UK). Splenocytes were isolated by manually
homogenizing spleens through a cell strainer and treating with
Hybri Max Red Blood Cell Lysing Buffer (Sigma- Aldrich). Blood
was collected from the carotid arteries into ‘microtainer’ serum
separation tubes or Vacutainer Vials (both BD Biosciences) and
serum was separated by centrifugation.
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Cytospin assay
BAL cells were spun onto slides, stained and lymphocytes were
counted as previously described [23]. Counts were performed
blind to experimental conditions.
Flow cytometry
1–106105 lung or BAL cells were stained with ‘live/dead
fixable dead cell stain’ (Invitrogen) and incubated with anti-mouse
CD16/CD32 (FC block; BD biosciences). Directly fluorochrome-
conjugated antibodies specific for CD3-Pacific Blue (clone 500A2),
CD4-APC (clone RM4-5), CD8-PE (clone 53-6.7), CD69-FITC
(clone H1.2F3), CD62L-PE (clone MEL-14) and CD44-FITC
(clone IM7) (all BD biosciences) were added directly. Cells were
fixed with 2% formaldehyde. For intracellular staining, lung cells
were stimulated for 4 hrs in media containing 50 ng/mL
Ionomycin, 500 ng/mL PMA (Both Sigma Aldrich) and golgi
transport inhibitor (Golgi Stop, BD Biosciences). Cells were then
surface stained as described, permeablised with 0.5% (w/v)
saponin (Sigma-Aldrich) and stained with fluorochrome conjugat-
ed anti-IFN-c-FITC (clone XMG1.2, BD biosciences).
Flow cytometry data was acquired using CyanADP (Dako,
USA) and FACSCanto (BD biosciences) cytometers and analysed
using Summit software (Dako, USA).
ELISA
Cytokine and chemokine proteins in BAL were assayed using
protocols and reagents from Duoset ELISA kits (R&D systems).
RV-specific IgG and IgA were measured using in-house assays
as described previously [36]. 96 well plates were coated overnight
with purified RV1B or RV29, as used for in vivo infections, and
blocked with 5% milk in PBS-0.05% tween 20. Samples were
pooled for each treatment group/timepoint, diluted as indicated in
5% milk blocking solution and plates were incubated for a further
2 hrs at room temperature. Detection antibodies were biotinylated
rat anti-mouse IgG1 (clone A85-1), IgG2a/c (clone R19-15) and
IgA (clone C10-1) (all BD biosciences) diluted in PBS 1% BSA.
Plates were then incubated with spreptavidin-HRP followed by
TMB substrate (both Invitrogen) and reactions were stopped by
addition of 1M H2SO4 For analysis of IgA in BAL, IgG was first
depleted by incubation with protein G sepharose beads (Sigma-
Aldrich). Antibody binding to HeLa cell lysate control coated wells
was measured in parallel in all assays and values were subtracted
from those of virus coated wells during analysis.
Cytometric Bead Array (CBA)
46105 splenocytes per well were distributed in 96 well plates
and stimulated with 1 mg/mL of RV peptide pools. Supernatants
were harvested after 3 days at 37uC. IL-5 and IFN-c concentra-
tions were measured using the mouse Th1/Th2 cytokine kit (BD
Biosciences) and a Facscalibur cytometer (Becton Dickinson). Data
was analyzed on FCAP Array software (Becton Dickinson).
ELISPOT
Assays were performed in 96 well multiscreen HA plates
(Millipore) coated with purified anti-mouse IFN-c or IL-5 (BD
biosciences). After blocking, 1 or 26105 lung cells were added,
followed by medium containing RV or control stimuli (RV16 VP0
protein (25 mg/mL), live RV1B (26106 TCID50/mL), RV
peptide pools (1 or 4 mg/mL), DMSO peptide pool control,
PMA/Ionomycin (50/500 ng/mL)). Plates were incubated for
18 hrs or 3 days at 37uC. Detection antibodies were biotinylated
rat anti-mouse IFN-c or IL-5 (BD biosciences). Plates were
subsequently incubated with streptavidin-horseradish peroxidase
(Southern Biotech) or extravidin alkaline phosphatase (Sigma-
Aldrich) followed by AEC or NBT/BCIP substrate (both Sigma-
Aldrich), respectively. Reactions were stopped with water.
Western blots
In immunogenicity experiments (Fig. 1), IgG responses were
analyzed by Western blot of pooled sera. 2 mg of recombinant viral
protein and molecular weight standard (SeeBluePlus2, Invitrogen)
were run on a 4–12% polyacrylamide SDS gel (Invitrogen).
Protein was transferred onto a nitrocellulose membrane (Bio-Rad,
USA) and blocked with 5% milk in PBS 0.05% Tween 20.
Membranes were probed with (1 in 200) diluted pooled mouse sera
followed by HRP-conjugated goat anti-mouse IgG (Jackson
ImmunoResearch, UK). Blots were developed colorimetrically
using 4-chloro-1-naphthol Opti-4CN substrate (Bio-Rad).
For the study of antibody cross-reactivity (Fig. S3) blots were
performed as described but with 1.25 mg virus protein (in vivo
inoculum) or 12.5 ng recombinant RV16 VP0. Detection
antibody was goat anti-mouse IgG (Santa Cruz biotechnology,
USA) and blots were developed using ECL (GE Healthcare, UK).
Neutralisation assays
Neutralisation of RV was measured in Ohio HeLa cells (UK
Health Protection Agency General Cell Collection catalogue
number 84121901). Sera for given treatment groups/timepoints
were pooled and incubated with purified RV at room temperature
with shaking for 1 hr, before addition of HeLa cells and further
incubation at 37uC for 48–96 hrs. Protection from CPE was
measured by crystal violet cell viability assay whereby cells were
stained with 0.1% (w/v) crystal violet, washed with water, air dried
and crystal violet was solubilised with 1% SDS. Absorbance was
measured at 560 nm.
Statistical analysis
Graphical data is expressed as mean +/2 SEM, representative
of at least 2 independent experiments. For all data differences
between treatment groups were assessed by one or two way
ANOVA and if significant (P,0.05) individual differences were
identified using bonferroni post-tests.
Supporting Information
Figure S1 Immunogen design. (a) Mean linear amino acid
sequence conservation amongst A (black line) and B (grey line) group
RVs. The mean conservation level was calculated at each position as
a sliding window of 30 amino acids in length. (b) Consensus amino
acid sequence for the VP0 protein of all available RVs showing
percentage conservation at each amino acid position. (c) Sequence of
the RV16 VP0 immunogen. (d) Amino acid alignment for the VP0
protein of RV strains used in peptide generation and in vivo
infections, with consensus sequence. (e) SDS-PAGE gel showing final
step purification of the RV16 VP0 immunogen. MW, molecular
weight marker. Lane a, SUMO VP0 protein after SUMO ULP-1
protease digestion. Lane b, cleaved HRV 16 VP0 protein after
IMAC purification. Lane c, eluted SUMO moiety, non-cleaved
protein and protease containing His tag.
(TIF)
Figure S2 Peptide pools Amino acid sequences of VP0
and 39 polymerase regions of RV1B and RV14 poly-
proteins. Those sequences used for generation of VP0 and
polymerase (39Pol) peptide pools, as described in methods, are
underlined.
(TIF)
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Figure S3 Serum and BAL antibody responses. (a–d) Mice
were immunized subcutaneously with RV16 VP0 protein plus
IFA/CpG, or with IFA/CpG adjuvant alone and infected
intranasally with RV1B, RV29 or sham infected with PBS, as
described. Sera and BAL were harvested at 6 and 14 days post-
infection, pooled and assayed for IgG and IgA binding to virus
inoculum preparations. (a) Serum and (b) BAL RV1B binding in
RV1B-infected or PBS-challenged mouse sera. (c) Serum and (d)
BAL RV29 binding in RV29-infected or PBS-challenged mouse
sera. (e) Mice were immunized twice with RV16 VP0 protein plus
IFA/CpG adjuvant subcutaneously and serum was harvested 6
weeks after immunization. Serum IgG binding to RV16 VP0
immunogen or to RV1B, RV29 and RV16 was assessed by
Western blot. HeLa; virus culture cell lysate control. VP0; viral
VP0 protein band estimated by molecular weight.
(TIF)
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